Develops cell engineering tools for biotechnology product manufacturers.
Jun 2026Revenue $112M/yrExpenses $403M/yr
No trendCash runway ≈ 6 months from Jun 2026
Figures by year
When will Ginkgo Bioworks Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $112M and expenses $403M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $170M | $485M | −$315M |
| Dec 2024 | $227M | $787M | −$560M |
| Dec 2023 | $251M | $1.12B | −$864M |
| Dec 2022 | $478M | $2.69B | −$2.21B |
| Dec 2021 | $314M | $2.14B | −$1.83B |
| Dec 2020 | $76.7M | $214M | −$137M |
| Dec 2019 | $54.2M | $126M | −$71.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.